Literature DB >> 30344905

New Dopamine D3-Selective Receptor Ligands Containing a 6-Methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol Motif.

Satishkumar Gadhiya1,2, Pierpaolo Cordone1,3, Rajat K Pal4,3, Emilio Gallicchio4,2,3, Lauren Wickstrom5, Tom Kurtzman6,2,3, Steven Ramsey6,3, Wayne W Harding1,2,3,6.   

Abstract

A series of analogues featuring a 6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol unit as the arylamine "head" group of a classical D3 antagonist core structure were synthesized and evaluated for affinity at dopamine D1, D2, and D3 receptors (D1R, D2R, D3R). The compounds generally displayed strong affinity for D3R with very good D3R selectivity. Docking studies at D2R and D3R crystal structures revealed that the molecules are oriented such that their arylamine units are positioned in the orthosteric binding pocket of D3R, with the arylamide "tail" units residing in the secondary binding pocket. Hydrogen bonding between Ser 182 and Tyr 365 at D3R stabilize extracellular loop 2 (ECL2), which in turn contributes to ligand binding by interacting with the "tail" units of the ligands in the secondary binding pocket. Similar interactions between ECL2 and the "tail" units were absent at D2R due to different positioning of the D2R loop region. The presence of multiple H-bonds with the phenol moiety of the headgroup of 7 and Ser192 accounts for its stronger D3R affinity as compared to the 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-containing analogue 8.

Entities:  

Year:  2018        PMID: 30344905      PMCID: PMC6187407          DOI: 10.1021/acsmedchemlett.8b00229

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  27 in total

1.  Conformationally-flexible benzamide analogues as dopamine D3 and sigma 2 receptor ligands.

Authors:  Robert H Mach; Yunsheng Huang; Rebekah A Freeman; Li Wu; Suwanna Vangveravong; Robert R Luedtke
Journal:  Bioorg Med Chem Lett       Date:  2004-01-05       Impact factor: 2.823

2.  Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist.

Authors:  Ellen Y T Chien; Wei Liu; Qiang Zhao; Vsevolod Katritch; Gye Won Han; Michael A Hanson; Lei Shi; Amy Hauck Newman; Jonathan A Javitch; Vadim Cherezov; Raymond C Stevens
Journal:  Science       Date:  2010-11-19       Impact factor: 47.728

Review 3.  The D3 dopamine receptor: neurobiology and potential clinical relevance.

Authors:  B Levant
Journal:  Pharmacol Rev       Date:  1997-09       Impact factor: 25.468

Review 4.  Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders.

Authors:  Christian A Heidbreder; Amy H Newman
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

5.  Occupancy of brain dopamine D3 receptors and drug craving: a translational approach.

Authors:  Manolo Mugnaini; Laura Iavarone; Palmina Cavallini; Cristiana Griffante; Beatrice Oliosi; Chiara Savoia; John Beaver; Eugenii A Rabiner; Fabrizio Micheli; Christian Heidbreder; Anne Andorn; Emilio Merlo Pich; Massimo Bani
Journal:  Neuropsychopharmacology       Date:  2012-09-12       Impact factor: 7.853

6.  Y-QA31, a novel dopamine D3 receptor antagonist, exhibits antipsychotic-like properties in preclinical animal models of schizophrenia.

Authors:  Xue Sun; Hong-yan Gou; Fei Li; Guan-yi Lu; Rui Song; Ri-fang Yang; Ning Wu; Rui-bin Su; Bin Cong; Jin Li
Journal:  Acta Pharmacol Sin       Date:  2016-01-18       Impact factor: 6.150

Review 7.  Dopamine: a key regulator to adapt action, emotion, motivation and cognition.

Authors:  André Nieoullon; Antoine Coquerel
Journal:  Curr Opin Neurol       Date:  2003-12       Impact factor: 5.710

8.  N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists.

Authors:  Amy Hauck Newman; Peter Grundt; George Cyriac; Jeffrey R Deschamps; Michelle Taylor; Rakesh Kumar; David Ho; Robert R Luedtke
Journal:  J Med Chem       Date:  2009-04-23       Impact factor: 7.446

9.  Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone.

Authors:  Sheng Wang; Tao Che; Anat Levit; Brian K Shoichet; Daniel Wacker; Bryan L Roth
Journal:  Nature       Date:  2018-01-24       Impact factor: 49.962

10.  Dopamine D3 receptor antagonist reveals a cryptic pocket in aminergic GPCRs.

Authors:  Noelia Ferruz; Stefan Doerr; Michelle A Vanase-Frawley; Yaozhong Zou; Xiaomin Chen; Eric S Marr; Robin T Nelson; Bethany L Kormos; Travis T Wager; Xinjun Hou; Anabella Villalobos; Simone Sciabola; Gianni De Fabritiis
Journal:  Sci Rep       Date:  2018-01-17       Impact factor: 4.379

View more
  3 in total

1.  New tetrahydroisoquinoline-based D3R ligands with an o-xylenyl linker motif.

Authors:  Pierpaolo Cordone; Hari K Namballa; Bryant Muniz; Rajat K Pal; Emilio Gallicchio; Wayne W Harding
Journal:  Bioorg Med Chem Lett       Date:  2021-04-18       Impact factor: 2.940

Review 2.  Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders.

Authors:  Béla Kiss; István Laszlovszky; Balázs Krámos; András Visegrády; Amrita Bobok; György Lévay; Balázs Lendvai; Viktor Román
Journal:  Biomolecules       Date:  2021-01-14

3.  Inclusion of enclosed hydration effects in the binding free energy estimation of dopamine D3 receptor complexes.

Authors:  Rajat Kumar Pal; Satishkumar Gadhiya; Steven Ramsey; Pierpaolo Cordone; Lauren Wickstrom; Wayne W Harding; Tom Kurtzman; Emilio Gallicchio
Journal:  PLoS One       Date:  2019-09-30       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.